Point View Wealth Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Point View Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$444K	Sell	46,052 -2,914	-6%	-$27.9K	0.18%	170
2020 Q3	$441K	Sell	48,966 -722	-1%	-$7.64K	0.21%	147
2020 Q2	$613K	Sell	49,688 -5,690	-10%	-$64.4K	0.29%	109
2020 Q1	$497K	Buy	55,378 +6,035	+12%	+$61.8K	0.27%	119
2019 Q4	$484K	Sell	49,343 -8,941	-15%	-$79.8K	0.2%	154
2019 Q3	$401K	Sell	58,284 -16,514	-22%	-$127K	0.18%	163
2019 Q2	$690K	Buy	74,798 +1,273	+2%	+$15.3K	0.29%	117
2019 Q1	$1.15M	Buy	73,525 +453	+0.6%	+$7.99K	0.51%	67
2018 Q4	$1.13M	Buy	73,072 +227	+0.3%	+$4.65K	0.57%	58
2018 Q3	$1.57M	Buy	72,845 +1,242	+2%	+$28.8K	0.7%	40
2018 Q2	$1.74M	Buy	71,603 +2,996	+4%	+$61.1K	0.81%	33
2018 Q1	$1.17M	Buy	68,607 +23,593	+52%	+$461K	0.56%	53
2017 Q4	$853K	Sell	45,014 -24,361	-35%	-$366K	0.4%	86
2017 Q3	$1.22M	Buy	69,375 +24,969	+56%	+$562K	0.59%	53
2017 Q2	$1.48M	Buy	44,406 +5,343	+14%	+$165K	0.73%	31
2017 Q1	$1.25M	Buy	39,063 +13,247	+51%	+$452K	0.65%	47
2016 Q4	$936K	Sell	25,816 -4,717	-15%	-$188K	0.54%	60
2016 Q3	$1.41M	Sell	30,533 -258	-0.8%	-$13.5K	0.83%	31
2016 Q2	$1.55M	Buy	30,791 +1,480	+5%	+$78.8K	0.94%	25
2016 Q1	$1.57M	Buy	29,311 +1,620	+6%	+$95.1K	1.01%	23
2015 Q4	$1.82M	Buy	27,691 +1,802	+7%	+$111K	1.31%	11
2015 Q3	$1.46M	Sell	25,889 -96	-0.4%	-$6.22K	1.17%	16
2015 Q2	$1.54M	Sell	25,985 -107	-0.4%	-$6.6K	1.19%	17
2015 Q1	$1.63M	Buy	26,092 +2,208	+9%	+$128K	1.26%	16
2014 Q4	$1.37M	Buy	23,884 +1,184	+5%	+$66K	1.02%	26
2014 Q3	$1.22M	Buy	22,700 +2,070	+10%	+$110K	1.04%	25
2014 Q2	$1.08M	Buy	20,630 +320	+2%	+$16.4K	0.94%	26
2014 Q1	$1.07M	Buy	20,310 +1,815	+10%	+$83.9K	0.98%	24
2013 Q4	$741K	Buy	+18,495	New	+$728K	0.7%	48

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Point View Wealth Management's TEVA Position: Q4 2020 in Review

Point View Wealth Management reduced its Teva Pharmaceutical Industries Limited (TEVA) stake by 6% in Q4 2020, selling an estimated $27.9K and leaving 46,052 shares worth $444K. The position accounts for 0.18% of the portfolio, ranked #170.

Point View Wealth Management first reported a position in TEVA in Q4 2013 and has held it in 29 quarters since. The position peaked at $1.82M in Q4 2015. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

Point View Wealth Management held 46,052 shares of Teva Pharmaceutical Industries Limited worth $444K as of Q4 2020.
Point View Wealth Management sold 2,914 Teva Pharmaceutical Industries Limited shares in Q4 2020, an estimated $27.9K.
Teva Pharmaceutical Industries Limited made up 0.18% of Point View Wealth Management's portfolio in Q4 2020, its #170 holding.
Point View Wealth Management first reported a position in Teva Pharmaceutical Industries Limited in Q4 2013 and has held it in 29 quarters since.
Point View Wealth Management's Teva Pharmaceutical Industries Limited position peaked at $1.82M in Q4 2015.
450 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2020.

Based on Point View Wealth Management's 13F filing for Q4 2020, filed 8 Feb 2021.